Skip to main content
All lobbying clients

ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA)

Lobbying client · District of Columbia · filed 2025 to 2026

Trade Organization for Generic Drug Manufacturers and Distributers

$420,000 Reported spend
7 Filings counted
1 Outside firm hired
16 Bills named

Spend is reported income plus in-house expenses across 7 filings. Everything on this page comes from one LDA client record (199174), filed by the registrant listed below.

 Who filed for this client 1

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings 16
  • S. 1414
    Expedited Access to Biosimilars Act
    6 filings
  • S. 1954
    Biosimilar Red Tape Elimination Act
    6 filings
  • S. 43
    Skinny Labels, Big Savings Act
    5 filings
  • S. 1041
    Affordable Prescriptions for Patients Act
    4 filings
  • S. 1302
    Increasing Transparency in Generic Drug Applications Act
    4 filings
  • S. 3788
    CLEAR LABELS Act
    3 filings
  • H.R. 3838
    Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fisc…
    2 filings
  • S. 2296
    National Defense Authorization Act for Fiscal Year 2026
    2 filings
  • S. 2658
    Medication Affordability and Patent Integrity Act
    2 filings
  • S. 3014
    Ensuring Timely Access to Generics Act of 2025
    2 filings
  • H.R. 7410
    American Made Medicine Act
    1 filing
  • H.R. 1262
    Mikaela Naylon Give Kids a Chance Act
    1 filing
  • S. 1096
    Preserve Access to Affordable Generics and Biosimilars Act
    1 filing
  • S. 3510
    Biosimilar Inspection Modernization Act of 2025
    1 filing
  • S. 4327
    Securing America’s Drug Supply from Communist China Act
    1 filing
  • S. 4784
    National Defense Authorization Act for Fiscal Year 2027
    1 filing
 Reported by year 2 years
  • 2026 $180,000 3 filings
  • 2025 $240,000 4 filings
 Issues lobbied 1

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 4
  • SENATE 7
  • HOUSE OF REPRESENTATIVES 4
  • Executive Office of the President (EOP) 1
  • Food & Drug Administration (FDA) 1
 Recent filings 7 total
Q3 report
FIERCE GOVERNMENT RELATIONS
3rd Quarter 2026 (July 1 - Sep 30) · Senate · $60,000 income · posted Oct 20, 2026
View → Q2 report
FIERCE GOVERNMENT RELATIONS
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 20, 2026
View → Q1 report
FIERCE GOVERNMENT RELATIONS
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $60,000 income · posted Apr 20, 2026
View → Q4 report
FIERCE GOVERNMENT RELATIONS
4th Quarter 2025 (Oct 1 - Dec 31) · Senate · $60,000 income · posted Jan 20, 2026
View → Q3 report
FIERCE GOVERNMENT RELATIONS
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 16, 2025
View → Q2 report
FIERCE GOVERNMENT RELATIONS
2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 21, 2025
View → Q1 report
FIERCE GOVERNMENT RELATIONS
1st Quarter 2025 (Jan 1 - Mar 31) · Senate · $60,000 income · posted Apr 21, 2025
View →

Keep going

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem